// App-Quantinova.ai

2588 : Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis

Researchers

Presenter

  • Kurt de Vlam

Principal Investigators

  • Andrew G Bushmakin

  • Joseph C Cappelleri

  • Philip J. Mease

  • Roy Fleischmann

  • Peter C. Taylor

  • Valderilio F Azevedo

  • Lara Fallon

  • Anna Maniccia

  • John Woolcott

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • KU Leuven, Leuven, Belgium

  • Pfizer, Groton, CT

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • University of Oxford, Oxford, United Kingdom

  • Universidade Federal do Parana (UFPR), Curitiba, Brazil.

  • Pfizer Canada, Montreal, QC, Canada

  • Pfizer Inc, New York, NY

  • Pfizer Inc, Collegeville, PA

Locations

  • United States

  • Belgium

  • United Kingdom

  • Brazil

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved